Tricida, Inc.
Tricida is a pharmaceutical company working to turn the tide on metabolic acidosis and progression of CKD.
South San Francisco, United States
16 employees
Post Ipo Debt
Total: $624.01M
Health Care, Pharmaceutical
General Information
Get notified when Tricida, Inc. moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Tricida, Inc.
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Health Care
About Tricida, Inc.
Taxonomy: pharmaceutical company, metabolic acidosis, chronic kidney disease, drug candidate, polymer-based treatment, therapeutics development, CKD progression, seasoned management team, therapeutics commercialization, polymer development, kidney-related diseases, veverimer, TRC101, non-absorbed drug, oral administration
Funding Rounds & Investors (9)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | •••••• | 1 |
|
19 Oct 2022 |
| Post-IPO Equity | •••••• | 3 |
|
15 Nov 2021 |
| Post-IPO Debt | •••••• | - | 22 May 2020 | |
| Debt Financing | •••••• | 1 |
|
02 Mar 2018 |
| Series D | •••••• | 8 |
|
08 Nov 2017 |
Tricida, Inc. Alternatives & Competitors
Pioneering targeted therapies to prevent and treat severe organ failure, with a focus on kidney dise...
Developing Therapeutics for Patients with Rare and Severe Metabolic and Kidney Disorders
Developing therapeutics for diseases with impaired kidney function
FAQ About Tricida, Inc.
Don't just browse. Track.
Signal Tracker monitors Tricida, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
